Transplantation. by McGeown, M. G.




I interpret my title as meaning organ transplantation. Corneal and skin grafts
differ from organ grafts in that they are not vascularised; in the former, immuno -
suppression is not needed to prevent rejection, while skin is very rapidly rejected
unless transplanted as an autograft or between identical twins. Grafts are
classified as: autograft, when the transplant is from the same individual, as is
usually the situation in skin grafts; isograft, when the donor and recipient are of
the same species and have identical genotypes - in other words, inbred litter
mates or identical twins; allograft, when the donor and recipient are of the same
species but their genotypes are different this is the usual situation in human
organ transplantation; and xenograft, when donor and recipient are of different
species. I will use kidney transplantation as my model and describe it in some
detail, not only because it is my own subject, but also because it developed earlier
than transplantation of other solid organs.
KIDNEY TRANSPLANTATION
Development
Kidney transplantation enjoys a number of advantages over transplantation of
other organs. The kidney is a duplicated organ and therefore a living donor can
be used. This made it possible to transplant a kidney between identical twins
without need for immunosuppression to prevent rejection, and such an isograft
was the first successful human organ transplant. The surgery required is straight-
forward: only one artery, one vein and the ureter of the donor organ need to be
anastomosed to the recipient's vessels and bladder. Transplantation of the liver,
heart, pancreas and heart -lung are technically much more difficult. The progress
of the grafted kidney can easily be monitored by urine volume and simple blood
tests. The position of the kidney in the iliac fossa enables it to be visualised easily
using imaging techniques such as ultrasound and renography. Rejection, if
suspected, can be diagnosed by percutaneous needle biopsy which is a simple
procedure; aspiration of a few kidney cells with a fine needle can even be carried
out daily. Kidney function can be replaced for long periods by artificial means and
the patient restored to relative health by dialysis treatment. And finally, the long
experience of kidney transplantation gives it a considerable advantage over that
involving other solid organs.
It was shown by Ullmann, in a demonstration to a Vienna medical society on
1 March 1902, that when the kidney in a dog was transplanted from its normal
site to the vessels in the neck, urine continued to be produced I evidence that
urine production does not require a nerve supply. That same year Decastello, at
another Vienna hospital, carried out dog-to-dog transplants,2 and these were
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emulated later by Ullmann.1 In both experiments urine was produced but neither
Ullmann nor Decastello continued this work, though both later achieved fame in
other fields. Carrel, also in Vienna, carried out autografts and later allografts of
kidneys in cats and dogs using improved methods of vascular suturing.3 He then
removed the recipient animal's own kidneys and found that the animal remained
well for a few days, after which urine production ceased. Jaboulay, Carrel's
teacher, is credited with the first human transplants.4 He carried out two
xenografts, transplanting a pig and a goat kidney into the arm orthigh of patients
with chronic renal failure. Each kidney worked for one houronly. Unger, in Berlin
in 1909, also attempted xenografts, grafting a still
-born kidney to a baboon, and
a kidney from a pig-ape to a young girl, but neither graft produced urine.5 In
1923 Williamson repeated the dog-to-dog experiment at the Mayo Foundation.
He described the histological appearance ofthe failed kidney for the first time.6,7
The first human allografts, that is human -to-human grafts, were carried out by
Voronoy in the Ukraine,8 six in all between 1933 and 1949. He used cadaver
kidneys but none achieved any useful function. In 1946 a group in Boston carried
out a human allograft using arm vessels, but it functioned only briefly.
In the early 1950s, the experimental work of Simonsen9' 10 and Dempster"
showed that immunological mechanisms were responsible for the rejection of
grafts. With this in mind, further attempts to transplant cadaver kidneys were
made in Paris by K(Jss,12 Servelle,'3 and Dubost,'4 and in Boston by Hume and
colleagues15 usually without using immunosuppression though small doses of
ACTH or cortisone were given to some patients. Surprisingly, the kidney survived
fora time in a few cases and this was attributed tothe relative immunosuppression
of uraemia. During this period it became clear that it was better to place the
transplanted kidney in the pelvis than superficially in the thigh.
Concomitantly, laboratory studies showed that skin could be transplanted
between litter mates but not between animals from different litters of the same
parentage; this suggested that itshould bepossible totransplant kidneys between
individuals with the same genetic inheritance without rejection occurring. This led
Murray et al in Boston in 1954 to carry out the first kidney transplant operation
between identical twins.'6 The kidney survived for eight years until recurrence of
the original nephritis led again to renal failure. Over the nextfive yearstransplant-
ation between identical twins was carried out in several centres in Europe and
America. Some failed for technical reasons but in none was there evidence of
rejection. The first transplant in Belfast was in 1962 between identical twins: it
was a technical failure. About this time Scribner described the semi-permanent
arteriovenous shunt which allowed patients to be kept alive by repeated haemo-
dialysis until a kidney became available for transplantation,17 an important
development whichgreatly facilitated thegrowthofarenaltransplant programme.
Immunosuppression
It is obvious that few patients reaching end-stage kidney failure are fortunate
enough to have an identical twin able and willing to provide a kidney. The
question was - could rejection be prevented when the graft was taken from a
less closely related individual? Total body irradiation as a means of immuno-
suppression was used prior to kidneytransplantation in Boston and Paris between
1958 and 1960. In Boston one out of 12 survived, a transplant from a non-
identical twin, and in Paris a sibling graft succeeded. These results indicated
that immunosuppression could work; the problem now was to find the most
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appropriate methods and regimens. Schwartz and Dameshek in Boston reasoned
that an anti-cancer drug such as 6-mercaptopurine might be used for immuno-
suppression and found that rabbits treated with this drug had little response to
injection of foreign protein.18 This led Calne in London to use this drug in kidney
transplants in dogs with success, though the drug was very toxic.19 Calne then
went to work in Boston and in 1960 tried out new derivatives of 6-mercaptopurine
which were produced by Hitchings of Burroughs Wellcome in New Jersey. One
of these, later known as azathioprine or Imuran, proved in dog kidney transplants
to be even more immunosuppressive as well as less toxic than the parent drug.20
In 1960-61, 6-mercaptopurine was used for human grafts in London by
Hopewell,2' in Boston by Murray and Caine, and in Paris by KOss.22 The only
success was Kuiss's patient who also received irradiation and intermittent
prednisone. Murray and Caine used azathioprine in 1962: their third case
succeeded, and despite several rejection episodes function continued for two
years. Azathioprine then became generally accepted as the main immuno-
suppressive drug for transplantation for the next two decades.
In 1962 Goodwin reported successful treatment with steroids of several rejection
episodes in a mother-to -child transplant, although the recipient finally died from
sepsis.23 After this, the combination of azathioprine and steroid was accepted as
standard for kidney transplantation. The general view at that time seems to have
been 'the more steroid the better', because this often permitted long-term
survival of kidney grafts, even though many patients died from infection: some
nephrologists preferred for their patients the greater safety of dialysis in spite of
the less good quality of life. Nevertheless, the age of drug immunosuppression
had arrived: the search was now on for an optimum regime.
Attempts were made by Woodruff24 in Edinburgh and Starzl25 in the USA to
develop a more specific weapon, antilymphocyte serum. This was produced in
horses by immunising them against peripheral blood lymphocytes, the cells
which infiltrate rejecting grafts. The antiserum has promising results in animals
but, on the whole, has proved disappointing in human transplantation. The anti -
lymphocyte serum has been purified to antilymphocyte globulin (ALG), the
spleen, thymus, or cultured lymphoblasts being used as the source of antigen.
Horse serum often produces reactions in patients and so small animals are
preferred, especially rabbits, though this greatly increases costs as each batch of
serum must be standardised and can only be tested in primates. ALG given along
with azathioprine and prednisolone is restricted to the early post -operative
period. It is now widely used in North America and in many European centres for
treatment of rejection episodes, but is little used in the United Kingdom. It
is associated with a high death rate due to opportunistic infections such
as cytomegalovirus infection, pneumocytosis, and toxoplasmosis. Rubin from
Boston, addressing the spring meeting of the British Transplantation Society in
April 1986, attributed the high death rate to the ALG rather than the accompany-
ing steroid. He also considers that the combination of ALG with any other
immunosuppressant greatly increases the risk of malignant tumours. The
recognition of these risks has been tardy.
From 1962 onwards Hamburger used tissue typing based on lymphocytes
it had long been realised that red cell compatibility was essential, and, if
transgressed, immediate rejection was the rule.26 Kissmeyer -Nielsen introduced
the direct cross-match between the serum of the recipient and the cells of the
donor in 1966, which must of course be negative.27
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At the end of 1968 in Belfast we began to transplant cadaver kidneys using the
combination of low dose steroid with azathioprine,28, 29 From the beginning we
were able to achieve two -year graft survival rates of over 80 per cent, well above
all other centres, and we can fairly claim to have been the first to demonstrate that
high doses of steroid were unnecessary and that the numerous steroid toxic
effects can largely be avoided. Furthermore, most patients escape Cushingoid
changes on our low dosage.
Blood transfusion from third party donors carries the risk of sensitisation of the
recipient against antigens present in the subsequent kidney donor. By the end of
the sixties the risk of producing cytotoxic antibodies led to a very cautious
approach to giving blood transfusions to patients who might be candidates for
renal transplantation. Eventually it was considered desirable to avoid giving any
blood transfusions at all. This policy, far from improving the results of transplant-
ation, paradoxically led to lower graft survival rates. This was not at first attributed
to the no-transfusion policy, but in 1974 Opelz and Terasaki reported that graft
survival was better in patients who had received transfusions than in those
not given blood.30 The conclusion was not generally accepted and their report
was criticised on the grounds that it was a multi- centre study with many other
differences in management besides transfusion. Over the next few years,
however, studies in animals, including rhesus monkeys, showed convincingly
that blood transfusion improved graft survival in most animals though a few were
sensitised and lost their grafts early on. Subsequently, this improvement in graft
survival with blood transfusion has been demonstrated in human recipients.
There is, however, no doubt that some subjects will develop antibodies and
unfortunately there is no way of identifying them in advance. Despite intensive
research we still do not understand how transfusion actually benefits transplants
and in the absence of a theoretical model we are uncertain as to the best way to
use transfusion.
The next development in immunosuppression took place after 1970. In 1972 at
the Sandoz Laboratories in Basle, Borel found that cyclosporin A, a fungal agent,
has potent immunosuppressant activity both in vitro and in viVo,31 and Caine and
White in 1976 -78 used it in dog kidney and pig heart transplants with excellent
graft survival. The drug was first used for human transplants by Calne in
Cambridge in 1978:32 he used it without steroid and considered the main
advantage to be the avoidance of steroid side effects. Despite this view many
centres now use steroids with cyclosporin A, sometimes in fairly low dose but
often in doses high by our standards. Cyclosporin A is now the most widely used
immunosuppressant drug in transplantation, notjust for kidney but for all types of
organ and bone marrow transplantation.
Cyclosporin A is not used at present for kidney transplantation in Belfast. In the
first place we have consistently attained a one and two year graft survival rate of
over 80% for cadaver grafts, and 95% for live donor grafts - among the best
experienced at any centre.33 Only by 1986 have some centres equalled our
performance. It has serious side effects more numerous than the leucopenia
and neoplasia associated with azathioprine. Two of these are of overwhelming
importance, nephrotoxicity and lymphoma. The former is dose-related and is
exceedingly common, occurring not only in transplanted kidneys but in normal
kidneys of patients given the drug for heart or bone marrow transplantation. It is
difficult to make aT clinical distinction between transplant rejection and nephro-
toxicity and even experienced renal pathologists sometimes find it impossible to
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make a cytological diagnosis on biopsy appearances. Blood cyclosporin A levels
may be of help but toxicity and blood levels do not correlate at all closely. The
distinction, however, is very important because if the decline in function is due to
toxicity it should improve when the dose is reduced. It was originally thought that
cyclosporin A toxic change was completely reversible, but interstitial fibrosis
in cyclosporin A-treated grafts has been reported from many centres; Myers and
colleagues in 1984 reported reduced glomerular filtration rate in heart transplant
patients treated with cyclosporin A, two of whom developed end-stage renal
failure, the kidneys showing interstitial fibrosis with focal glomerular sclerosis.34
Experience on the long-term survival of cyclosporin A grafts will soon become
available. Our own experience with azathioprine in the long-term is shown in the
Table. Our first 100 grafts were done over ten years ago. Ninety-seven were
cadaver grafts, three werefrom living related donors. Forty-seven patients survive
with functioning grafts for ten to over 17 years. Twenty-one died with well-
functioning grafts between six months and 15 years after transplant. There were
twoearly deathswith functioning grafts. Thirty grafts have failed (not duetodeath)
over the whole period of 16 years.
TABLE
Fate of the first 100 renal transplants in Belfast, to 31 December 1985
No
Grafts surviving 10 - 15 + years 47
Died with functioning graft after six months - 15 years 21
Early death functioning graft 2
Failed grafts 30
Total 100
The second important side effect of cyclosporin A is lymphoma. The earliest
cases reported by Calne occurred within a few months, and there were four in the
first 32 patients, which he attributed to the large dose used.32 Other centres
reporting lymphomata also used quite high doses, though less than Cambridge
did initially. Much lower doses are now being used; some centres have switched
to azathioprine and steroid after two to six months on cyclosporin treatment but
some grafts have been lost from rejection at the change-over. The incidence of
neoplasia at the more recent, lower doses is not yet known. Neoplasia of course
also occurs with azathioprine: one of our patients died of acute monoblastic
leukaemia, two have developed basal cell carcinoma, and seven squamous
carcinoma. I am all too uneasily aware that we have given too much azathioprine
in the past and we now reduce it for long-term grafts.
Other immunosuppressants have been tested: for example, monoclonal
antibodies which are more specific forms of ALG have been used in human
transplantation, but although early reports by Cosimi were exciting they seem to
be more helpful in the laboratory than for clinical situations.35 Total lymphoid
irradiation, pioneered by Myburgh in Johannesburg using baboons,36 utilises
irradiation of an inverted Y area of the body similar to that used for treatment of
Hodgkin's disease, but, when used for human transplantation, mortality is high.
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Triple therapy (cyclosporin A, steroid and azathioprine) or even quadruple
therapy (cyclosporin A, steroid, azathioprine and ALG) have been tried in several
centres on small series of patients but so far with equivocally significant results.
There is no strong evidence that cyclosporin A is superior to the Belfast regimen
of azathioprine plus steroid. Eurotransplant reported in October 1985 a first
cadaver graft of 82% at one year using cyclosporin A, a result no better than
our own. Furthermore, all methods of immunosuppression have serious side
effects and are less than fully effective. The great hope is that a better derivative
of cyclosporin A may be obtained, but the analogues cyclosporin B, C, D, E
and F are not immunosuppressive, and while G is immunosuppressive, its side
effects are not yet known.
Developments in tissue typing have taken place over the past twenty years and
have led to the setting
-up of collaborative organisations for exchange of kidneys
to obtain better matching - UKTransplant, Eurotransplant and Scandiatransplant
all exist for this purpose, and there are links between the three computers so that
rare genotypes can be matched. The exchange of kidneys has been facilitated by
improvements in harvesting cadaver transplants - better perfusion fluids, in situ
perfusion, and acceptance of the concept of heart-beating brain -dead donors.
OPINION
I have used kidney transplantation throughout as a model. Except for tissue
typing, all these aspects are relevant to other organ transplants. ABO matching
alone is used for liver, heart, and heart
-lung grafts because thereis no satisfactory
artificial method of replacement of these organs equivalent to dialysis: if a graft
cannot be found quickly, the patient will die. Besides the technical difficulties of
transplanting a liver, heart or heart-lung preparation there are some special
constraints. The donor organ is needed urgently as the patient is already in
advanced organ failure when selected. Only patients aged less than 45 are
considered (we have successful kidney transplants up to the age of 71), and
the donor must be young, certainly less than 35, and matched for size with the
recipient. Furthermore, in heart-lung transplantation, the donor must be in
the same hospital as the recipient and this raises the problem of moving a dying
patient. But in spite of these additional problems remarkably good results have
been obtained with heart, liverand, very recently, with heart-lung transplantation.
The results with the pancreas are, however, less satisfactory for there is the
special problem of dealing with its exocrine function, and in the human it has not
yet proved possible to transplant separated Islets of Langerhans.
It has become fashionable to knock 'hi-tech' medicine, deriding it for syphoning
scarce resources from other areas of health care for the benefit of a few. Organ
transplantation is the acme of 'hi-tech' medicine, but it is indeed a very real
advance. Chronic renal failure is no respecter of persons and occurs.from early
childhood to old age. Less than 25 years ago it was a death sentence, a more
certain one than even cancer orleukaemia, for which someform oftreatment was
often possible. As an example I can cite the case of Anna, who developed end-
stage renal failure atthe ageof 16. She had two spellsofhaemodialysis, separated
by a transplant which functioned for about three years, during which her
daughter, Julie, was born. Two years after a second transplant Sean was born
and Anna had a third child in November 1985. Without the derided 'hi-tech'
medicine arid the years of patient, constructive and innovative research which
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has made it possible and which might indeed make many other life-saving
developments possible also, Anna would have died at sixteen instead of being a
lovely and fulfilled young woman.
Despite these arguments transplantation does produce real dilemmas because
resources are insufficient to permit treatment of all who might benefit.37 How to
decide who should have treatment? That is the question. Many more patients
could be treated even with our present restricted facilities if there were more
kidney donors. We know, and you know, that many suitable donors are lost, and
this is not entirely due to reluctance ofthe public to allow organ donation. Doctors
have a responsibility also. Transplantation doctors have discussed whether
legislation might help, particularly an 'opting-out' scheme - that is, that it is for
the individual to register an objection to donation if he has one, and if no such
objection is registered permission is assumed. Manchester has tried 'opting-in'
by registering willingness to donate on a computer connected to the intensive
care units in the area, but after two years only 200,000 have registered whereas
1,000,000 would be needed to be useful. Some States in the USA have
introduced legislation to make it compulsory to request donation before turning
off life support machines. Neither 'opting-out' nor 'opting-in' appears so far
particularly helpful but the USA scheme is reported to have increased the
numbers of donors.
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